The popularity of Sildenafil initially fueled a period of growth for major pharmaceutical companies, but recent developments present a complicated scenario for shareholders. Generic versions are eating into revenue, https://francesypvp373376.buyoutblog.com/41221061/sildenafil-and-the-pharmaceutical-industry-a-precarious-bet